Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension

Exclusion Criteria

• •Exercise limitation related to a non-cardiopulmonary reason (e.g. arthritis)
• •Severe systemic hypertension \> 170/95
• •Patients with congestive heart failure (left ventricular dysfunction) or primary right ventricular dysfunction
• •Anticipation by the investigator for escalation in sarcoidosis treatment during the course of the study
• •Pulmonary hypertension related to etiology other than sarcoidosis (i.e. HIV, scleroderma, etc.)
• •Use within 1 month of an endothelin receptor antagonists (bosentan, sitaxsentan).
• •WHO functional class IV status
• •Patients with significant left ventricular dysfunction
• •Significant liver dysfunction not due to sarcoidosis.
• •Patients with severe other organ disease felt by investigators to impact on survival during the course of the study.